Randomized trial · people
Tirzepatide SURMOUNT-MAINTAIN: 21.9% weight loss at 112 weeks
Checked against the paper Randomized trialPublished by PepVault
The takeaway
Keeping tirzepatide at the full tolerated dose held weight off best over a further year, a lower 5 mg dose kept much of the loss, and switching to placebo led to regain in many people.
- Kind
- Randomized trial
- Studied in
- People
- Number studied
- 378
- Published
- 2026
- Journal
- Lancet
What they tested
After weight loss on tirzepatide, does staying on the top tolerated dose or dropping to 5 mg keep the weight off better than switching to placebo?
How the study was done
A phase 3b, double-blind, randomized, placebo-controlled trial at 20 US sites in adults with obesity, or overweight plus a weight-related health problem. Everyone first took weekly tirzepatide injections at their maximum tolerated dose (MTD, 10 mg or 15 mg) for 60 weeks, then 378 people were split to stay on the MTD (140), drop to 5 mg (144) or switch to placebo, a dummy shot (94), for 52 more weeks.

Model. Individual results vary.
What they found
From the start of the trial to week 112, body weight changed by -21.9% in the MTD arm, -16.6% in the 5 mg arm and -9.9% in the placebo arm, and both tirzepatide arms beat placebo (p<0.0001). Rescue tirzepatide, offered from week 84 to people who regained more than 50% of the weight they had lost, went to 11 of 138 (8%) in the MTD arm, 35 of 142 (25%) in the 5 mg arm and 60 of 90 (67%) in the placebo arm. The most common side effects with tirzepatide were stomach and gut problems, mostly mild to moderate and mostly during dose increases.
What it doesn’t show
Only people who finished the 60-week weight-loss phase on tirzepatide were randomized, and the placebo arm could get rescue tirzepatide, so this is not a test of stopping with no further treatment. The trial ran only in the USA, most participants were White and female, and it was funded by Eli Lilly.
The paper
Horn et al. Tirzepatide for maintenance of bodyweight reduction in people with obesity in the USA (SURMOUNT-MAINTAIN): a multicentre, double-blind, randomised, placebo-controlled trial. Lancet. 2026.
The compound
More studies on Tirzepatide
- Tirzepatide plus apitegromab: 1.9 kg less lean mass loss in EMBRAZERandomized trial · people · 2026
- Dulaglutide: switching to tirzepatide beat dose escalation on HbA1cRandomized trial · people · 2025
- Tirzepatide: up to 19.7% weight loss at 176 weeks in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: about 75% of weight lost was fat in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: most reached a weight plateau by week 72 in SURMOUNT-1Randomized trial · people · 2025
- Tirzepatide: 20.2% weight loss vs 13.7% on semaglutide at 72 weeksRandomized trial · people · 2025
- Every study on Tirzepatide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.